-
1
-
-
42049096072
-
Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency
-
Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28:413-437.
-
(2008)
Immunol Allergy Clin North Am
, vol.28
, pp. 413-437
-
-
Berger, M.1
-
2
-
-
48649085583
-
Common variable immunodeficiency: a new look at an old disease
-
Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet 2008; 372:489-502.
-
(2008)
Lancet
, vol.372
, pp. 489-502
-
-
Park, M.A.1
Li, J.T.2
Hagan, J.B.3
Maddox, D.E.4
Abraham, R.S.5
-
3
-
-
84920273342
-
-
American Academy of Allergy Asthma and Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. Milwaukee, WI, USA
-
American Academy of Allergy Asthma and Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. Milwaukee, WI, USA, 2011.
-
(2011)
-
-
-
4
-
-
0034073949
-
The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
-
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94-100.
-
(2000)
J Clin Immunol
, vol.20
, pp. 94-100
-
-
Chapel, H.M.1
Spickett, G.P.2
Ericson, D.3
Engl, W.4
Eibl, M.M.5
Bjorkander, J.6
-
5
-
-
34548665264
-
Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency
-
Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96:1474-1478.
-
(2007)
Acta Paediatr
, vol.96
, pp. 1474-1478
-
-
Fasth, A.1
Nystrom, J.2
-
6
-
-
0029908505
-
Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies
-
Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics 1996; 98:1127-1131.
-
(1996)
Pediatrics
, vol.98
, pp. 1127-1131
-
-
Abrahamsen, T.G.1
Sandersen, H.2
Bustnes, A.3
-
7
-
-
0028857579
-
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs
-
Gardulf A, Andersen V, Bjorkander J etal. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365-369.
-
(1995)
Lancet
, vol.345
, pp. 365-369
-
-
Gardulf, A.1
Andersen, V.2
Bjorkander, J.3
-
8
-
-
0036751568
-
Express subcutaneous IgG infusions: decreased time of delivery with maintained safety
-
Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2002; 104:237-241.
-
(2002)
Clin Immunol
, vol.104
, pp. 237-241
-
-
Hansen, S.1
Gustafson, R.2
Smith, C.I.3
Gardulf, A.4
-
9
-
-
0025738608
-
Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion
-
Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:162-166.
-
(1991)
Lancet
, vol.338
, pp. 162-166
-
-
Gardulf, A.1
Hammarstrom, L.2
Smith, C.I.3
-
10
-
-
0020960844
-
Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin
-
Welch MJ, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 1983; 3:285-286.
-
(1983)
J Clin Immunol
, vol.3
, pp. 285-286
-
-
Welch, M.J.1
Stiehm, E.R.2
-
11
-
-
77957580751
-
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency
-
Hagan JB, Fasano MB, Spector S etal. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734-745.
-
(2010)
J Clin Immunol
, vol.30
, pp. 734-745
-
-
Hagan, J.B.1
Fasano, M.B.2
Spector, S.3
-
12
-
-
80255138611
-
Efficacy and safety of subcutaneous Vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study
-
Borte M, Quinti I, Soresina A etal. Efficacy and safety of subcutaneous Vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol 2011; 31:952-961.
-
(2011)
J Clin Immunol
, vol.31
, pp. 952-961
-
-
Borte, M.1
Quinti, I.2
Soresina, A.3
-
13
-
-
84920262371
-
-
International Patient Organisation for Primary Immunodeficiencies. IPOPI PID Patient Needs and Outlooks Survey. Cornwall, UK
-
International Patient Organisation for Primary Immunodeficiencies. IPOPI PID Patient Needs and Outlooks Survey. Cornwall, UK, 2012.
-
(2012)
-
-
-
14
-
-
80255127287
-
Subcutaneous immunoglobulin replacement therapy in infants and children with primary immunodeficiencies
-
Church JA, Howard V, Sleasman JW, Borte M, Berger M. Subcutaneous immunoglobulin replacement therapy in infants and children with primary immunodeficiencies. J Allergy Clin Immunol 2011; 127:AB213.
-
(2011)
J Allergy Clin Immunol
, vol.127
, pp. AB213
-
-
Church, J.A.1
Howard, V.2
Sleasman, J.W.3
Borte, M.4
Berger, M.5
-
15
-
-
77956615735
-
Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies
-
Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
-
(2010)
Clin Immunol
, vol.137
, pp. 21-30
-
-
Orange, J.S.1
Grossman, W.J.2
Navickis, R.J.3
Wilkes, M.M.4
-
16
-
-
84863599753
-
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
-
Orange JS, Belohradsky BH, Berger M etal. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169:172-181.
-
(2012)
Clin Exp Immunol
, vol.169
, pp. 172-181
-
-
Orange, J.S.1
Belohradsky, B.H.2
Berger, M.3
-
17
-
-
84888336146
-
Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease
-
Bonagura VR. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Ann Allergy Asthma Immunol 2013; 111:S10-S13.
-
(2013)
Ann Allergy Asthma Immunol
, vol.111
, pp. S10-S13
-
-
Bonagura, V.R.1
-
18
-
-
77955266751
-
Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency
-
Freiberger T, Grodecka L, Ravcukova B etal. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010; 136:419-425.
-
(2010)
Clin Immunol
, vol.136
, pp. 419-425
-
-
Freiberger, T.1
Grodecka, L.2
Ravcukova, B.3
-
19
-
-
77952741985
-
Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years
-
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-1360.
-
(2010)
J Allergy Clin Immunol
, vol.125
, pp. 1354-1360
-
-
Lucas, M.1
Lee, M.2
Lortan, J.3
Lopez-Granados, E.4
Misbah, S.5
Chapel, H.6
-
20
-
-
46049100774
-
Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection
-
Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210-212.
-
(2008)
J Allergy Clin Immunol
, vol.122
, pp. 210-212
-
-
Bonagura, V.R.1
Marchlewski, R.2
Cox, A.3
Rosenthal, D.W.4
-
21
-
-
4944262622
-
Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home
-
Gardulf A, Nicolay U, Math D etal. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
-
(2004)
J Allergy Clin Immunol
, vol.114
, pp. 936-942
-
-
Gardulf, A.1
Nicolay, U.2
Math, D.3
-
22
-
-
1342333895
-
Pulmonary complications of primary immunodeficiencies
-
Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 2004; 5 (Suppl. A):S225-233.
-
(2004)
Paediatr Respir Rev
, vol.5
, pp. S225-S233
-
-
Buckley, R.H.1
-
23
-
-
37249071407
-
Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy
-
Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:81-88.
-
(2008)
Clin Immunol
, vol.126
, pp. 81-88
-
-
Gardulf, A.1
Borte, M.2
Ochs, H.D.3
Nicolay, U.4
-
24
-
-
30944444864
-
Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
-
Nicolay U, Kiessling P, Berger M etal. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65-72.
-
(2006)
J Clin Immunol
, vol.26
, pp. 65-72
-
-
Nicolay, U.1
Kiessling, P.2
Berger, M.3
-
25
-
-
33750842089
-
Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies
-
Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:434-442.
-
(2006)
Curr Opin Allergy Clin Immunol
, vol.6
, pp. 434-442
-
-
Gardulf, A.1
Nicolay, U.2
-
26
-
-
0027180544
-
The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions
-
Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 1993; 92:200-204.
-
(1993)
Clin Exp Immunol
, vol.92
, pp. 200-204
-
-
Gardulf, A.1
Bjorvell, H.2
Gustafson, R.3
Hammarstrom, L.4
Smith, C.I.5
-
27
-
-
84883252281
-
Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review
-
Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs 2013; 73:1307-1319.
-
(2013)
Drugs
, vol.73
, pp. 1307-1319
-
-
Lingman-Framme, J.1
Fasth, A.2
-
28
-
-
46749117598
-
Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin
-
Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28:370-378.
-
(2008)
J Clin Immunol
, vol.28
, pp. 370-378
-
-
Fasth, A.1
Nystrom, J.2
-
29
-
-
84860443133
-
Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases
-
Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 2012; 46:315-321.
-
(2012)
Transfus Apher Sci
, vol.46
, pp. 315-321
-
-
Haddad, E.1
Barnes, D.2
Kafal, A.3
-
30
-
-
84875701053
-
Controversies in IgG replacement therapy in patients with antibody deficiency diseases
-
Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131:1001-1005.
-
(2013)
J Allergy Clin Immunol
, vol.131
, pp. 1001-1005
-
-
Gelfand, E.W.1
Ochs, H.D.2
Shearer, W.T.3
-
31
-
-
84862865305
-
Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology
-
Orange JS, Ballow M, Stiehm ER etal. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2012; 130:S1-24.
-
(2012)
J Allergy Clin Immunol
, vol.130
, pp. S1-24
-
-
Orange, J.S.1
Ballow, M.2
Stiehm, E.R.3
-
32
-
-
10744229712
-
Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial
-
Roifman CM, Schroeder H, Berger M etal. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3:1325-1333.
-
(2003)
Int Immunopharmacol
, vol.3
, pp. 1325-1333
-
-
Roifman, C.M.1
Schroeder, H.2
Berger, M.3
-
33
-
-
84885182424
-
Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina
-
Bezrodnik L, Gomez RA, Belardinelli G etal. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol 2013; 33:1216-1222.
-
(2013)
J Clin Immunol
, vol.33
, pp. 1216-1222
-
-
Bezrodnik, L.1
Gomez, R.A.2
Belardinelli, G.3
-
34
-
-
84866740512
-
Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency
-
Empson MB, Tang ML, Pearce LK etal. Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam(R), in primary immunodeficiency. J Clin Immunol 2012; 32:897-906.
-
(2012)
J Clin Immunol
, vol.32
, pp. 897-906
-
-
Empson, M.B.1
Tang, M.L.2
Pearce, L.K.3
-
35
-
-
84861736225
-
Comparison of American and European practices in the management of patients with primary immunodeficiencies
-
Hernandez-Trujillo HS, Chapel H, Lo Re V III etal. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012; 169:57-69.
-
(2012)
Clin Exp Immunol
, vol.169
, pp. 57-69
-
-
Hernandez-Trujillo, H.S.1
Chapel, H.2
Lo Re III, V.3
-
36
-
-
84901596592
-
Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America
-
Condino-Neto A, Costa-Carvalho BT, Grumach AS etal. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Allergol Immunopathol (Madr) 2014; 42:245-260.
-
(2014)
Allergol Immunopathol (Madr)
, vol.42
, pp. 245-260
-
-
Condino-Neto, A.1
Costa-Carvalho, B.T.2
Grumach, A.S.3
-
37
-
-
84889878773
-
Subcutaneous immunoglobulin replacement therapy: the European experience
-
Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: the European experience. Curr Opin Allergy Clin Immunol 2013; 13:623-629.
-
(2013)
Curr Opin Allergy Clin Immunol
, vol.13
, pp. 623-629
-
-
Chapel, H.1
Gardulf, A.2
-
38
-
-
80255138210
-
Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose
-
Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011; 11:532-538.
-
(2011)
Curr Opin Allergy Clin Immunol
, vol.11
, pp. 532-538
-
-
Berger, M.1
-
39
-
-
84891719754
-
Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency
-
Landersdorfer CB, Bexon M, Edelman J etal. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med 2013; 125:53-61.
-
(2013)
Postgrad Med
, vol.125
, pp. 53-61
-
-
Landersdorfer, C.B.1
Bexon, M.2
Edelman, J.3
-
40
-
-
53849119869
-
Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes
-
ix.
-
Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:803-819. ix.
-
(2008)
Immunol Allergy Clin North Am
, vol.28
, pp. 803-819
-
-
Bonilla, F.A.1
-
41
-
-
0034020054
-
Lymphatic transport of proteins after subcutaneous administration
-
Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89:297-310.
-
(2000)
J Pharm Sci
, vol.89
, pp. 297-310
-
-
Porter, C.J.1
Charman, S.A.2
-
42
-
-
42049112189
-
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies
-
Gustafson R, Gardulf A, Hansen S etal. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008; 152:274-279.
-
(2008)
Clin Exp Immunol
, vol.152
, pp. 274-279
-
-
Gustafson, R.1
Gardulf, A.2
Hansen, S.3
-
43
-
-
80255138608
-
Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency
-
Borte M, Pac M, Serban M etal. Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol 2011; 31:752-761.
-
(2011)
J Clin Immunol
, vol.31
, pp. 752-761
-
-
Borte, M.1
Pac, M.2
Serban, M.3
-
44
-
-
84920265424
-
Experience with a 20% subcutaneous immunoglobulin (Hizentra) in children with primary immunodeficiency diseases - a single-center review
-
Gregory R, Malcolmson C, Patel C, Woolley T, Jones A. Experience with a 20% subcutaneous immunoglobulin (Hizentra) in children with primary immunodeficiency diseases - a single-center review. J Allergy Clin Immunol 2013; 131:AB154.
-
(2013)
J Allergy Clin Immunol
, vol.131
, pp. AB154
-
-
Gregory, R.1
Malcolmson, C.2
Patel, C.3
Woolley, T.4
Jones, A.5
-
45
-
-
84920287183
-
Quantification of the wear-off effect towards the end of the intravenous immunoglobulin infusion interval: pooled data analysis
-
Lawo J-P, Hubsch A, Rojavin M. Quantification of the wear-off effect towards the end of the intravenous immunoglobulin infusion interval: pooled data analysis. J Allergy Clin Immunol 2014; 133:AB179.
-
(2014)
J Allergy Clin Immunol
, vol.133
, pp. AB179
-
-
Lawo, J.-P.1
Hubsch, A.2
Rojavin, M.3
-
47
-
-
82455163980
-
Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach
-
Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach. Adv Ther 2011; 28:521-533.
-
(2011)
Adv Ther
, vol.28
, pp. 521-533
-
-
Jolles, S.1
Sleasman, J.W.2
-
48
-
-
84920269771
-
New frontiers in subcutaneous immunoglobulin treatment
-
Jolles S, Stein MR, Longhurst HJ etal. New frontiers in subcutaneous immunoglobulin treatment. Biol Ther 2011; 1:3-18.
-
(2011)
Biol Ther
, vol.1
, pp. 3-18
-
-
Jolles, S.1
Stein, M.R.2
Longhurst, H.J.3
-
49
-
-
84880713148
-
Adverse effects of human immunoglobulin therapy
-
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27:171-178.
-
(2013)
Transfus Med Rev
, vol.27
, pp. 171-178
-
-
Stiehm, E.R.1
-
50
-
-
84920282437
-
Immunologists' attitudes on 'wear-off' effects of IgG replacement therapy for primary immunodeficiency disease (PIDD) patients
-
Ballow M, Bullinger A, Murphy E, Berger M. Immunologists' attitudes on 'wear-off' effects of IgG replacement therapy for primary immunodeficiency disease (PIDD) patients. J Allergy Clin Immunol 2013; 131:AB156.
-
(2013)
J Allergy Clin Immunol
, vol.131
, pp. AB156
-
-
Ballow, M.1
Bullinger, A.2
Murphy, E.3
Berger, M.4
-
51
-
-
33645341439
-
Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
-
Orange JS, Hossny EM, Weiler CR etal. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117:S525-553.
-
(2006)
J Allergy Clin Immunol
, vol.117
, pp. S525-S553
-
-
Orange, J.S.1
Hossny, E.M.2
Weiler, C.R.3
-
52
-
-
17444424564
-
Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
-
Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005; 6:24-29.
-
(2005)
Eur J Health Econ
, vol.6
, pp. 24-29
-
-
Hogy, B.1
Keinecke, H.O.2
Borte, M.3
-
53
-
-
0029071368
-
A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home
-
Gardulf A, Moller G, Jonsson E. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care 1995; 11:345-353.
-
(1995)
Int J Technol Assess Health Care
, vol.11
, pp. 345-353
-
-
Gardulf, A.1
Moller, G.2
Jonsson, E.3
-
54
-
-
84873405539
-
Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center
-
Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2013; 131:585-587.
-
(2013)
J Allergy Clin Immunol
, vol.131
, pp. 585-587
-
-
Ducruet, T.1
Levasseur, M.C.2
Des Roches, A.3
Kafal, A.4
Dicaire, R.5
Haddad, E.6
-
55
-
-
84872681374
-
Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
-
Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med 2013; 23:55-60.
-
(2013)
Transfus Med
, vol.23
, pp. 55-60
-
-
Martin, A.1
Lavoie, L.2
Goetghebeur, M.3
Schellenberg, R.4
-
56
-
-
84920267477
-
-
Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Towson, MD, USA
-
Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Towson, MD, USA, 2003.
-
(2003)
-
-
-
57
-
-
84887011778
-
The variable in common variable immunodeficiency: a disease of complex phenotypes
-
Jolles S. The variable in common variable immunodeficiency: a disease of complex phenotypes. J Allergy Clin Immunol Pract 2013; 1:545-556.
-
(2013)
J Allergy Clin Immunol Pract
, vol.1
, pp. 545-556
-
-
Jolles, S.1
-
58
-
-
84920273827
-
The utility of anti-pneumococcal antibody measurement in patients with primary immunodeficiency receiving immunoglobulin
-
Jolles S, Heaps A, Moody M, Jones R. The utility of anti-pneumococcal antibody measurement in patients with primary immunodeficiency receiving immunoglobulin. J Allergy Clin Immunol 2014; 133:AB68.
-
(2014)
J Allergy Clin Immunol
, vol.133
, pp. AB68
-
-
Jolles, S.1
Heaps, A.2
Moody, M.3
Jones, R.4
-
59
-
-
0030793979
-
Human intravenous immunoglobulin in primary and secondary antibody deficiencies
-
Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997; 16:696-707.
-
(1997)
Pediatr Infect Dis J
, vol.16
, pp. 696-707
-
-
Stiehm, E.R.1
-
60
-
-
0027602669
-
New insights into common variable immunodeficiency
-
Sneller MC, Strober W, Eisenstein E, Jaffe JS, Cunningham Rundles C. New insights into common variable immunodeficiency. Ann Intern Med 1993; 118:720-730.
-
(1993)
Ann Intern Med
, vol.118
, pp. 720-730
-
-
Sneller, M.C.1
Strober, W.2
Eisenstein, E.3
Jaffe, J.S.4
Cunningham Rundles, C.5
-
62
-
-
0033511446
-
Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients
-
Quartier P, Debre M, De Blic J etal. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999; 134:589-596.
-
(1999)
J Pediatr
, vol.134
, pp. 589-596
-
-
Quartier, P.1
Debre, M.2
De Blic, J.3
-
63
-
-
77950628870
-
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
-
Yong PL, Boyle J, Ballow M etal. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Clin Immunol 2010; 135:255-263.
-
(2010)
Clin Immunol
, vol.135
, pp. 255-263
-
-
Yong, P.L.1
Boyle, J.2
Ballow, M.3
-
64
-
-
84920278833
-
-
Immune Deficiency Foundation. Primary immunodeficiency diseases in America: 2007 - the third national survey of patients. Towson, MD, USA
-
Immune Deficiency Foundation. Primary immunodeficiency diseases in America: 2007 - the third national survey of patients. Towson, MD, USA, 2009.
-
(2009)
-
-
-
65
-
-
0028173922
-
Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency
-
Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994; 14:90-97.
-
(1994)
J Clin Immunol
, vol.14
, pp. 90-97
-
-
Waniewski, J.1
Gardulf, A.2
Hammarstrom, L.3
-
66
-
-
77953535202
-
Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis
-
Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010; 30:301-307.
-
(2010)
J Clin Immunol
, vol.30
, pp. 301-307
-
-
Shapiro, R.1
-
67
-
-
84879551412
-
Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis
-
Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013; 111:51-55.
-
(2013)
Ann Allergy Asthma Immunol
, vol.111
, pp. 51-55
-
-
Shapiro, R.S.1
-
68
-
-
77954393427
-
Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
-
Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010; 15:238-245.
-
(2010)
Eur J Med Res
, vol.15
, pp. 238-245
-
-
Hoffmann, F.1
Grimbacher, B.2
Thiel, J.3
Peter, H.H.4
Belohradsky, B.H.5
-
69
-
-
33745040276
-
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study
-
Gardulf A, Nicolay U, Asensio O etal. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26:177-185.
-
(2006)
J Clin Immunol
, vol.26
, pp. 177-185
-
-
Gardulf, A.1
Nicolay, U.2
Asensio, O.3
-
70
-
-
84876439912
-
Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States
-
Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol 2013; 33:49-54.
-
(2013)
J Clin Immunol
, vol.33
, pp. 49-54
-
-
Huang, F.1
Feuille, E.2
Cunningham-Rundles, C.3
-
71
-
-
84920268263
-
Bioavailability of IgG administered by the subcutaneous route
-
Berger M, Jolles S, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Allergy Clin Immunol 2012; 129:AB114.
-
(2012)
J Allergy Clin Immunol
, vol.129
, pp. AB114
-
-
Berger, M.1
Jolles, S.2
Sleasman, J.W.3
-
72
-
-
77953292119
-
Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates
-
Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol 2010; 30:442-448.
-
(2010)
J Clin Immunol
, vol.30
, pp. 442-448
-
-
Sleasman, J.W.1
Duff, C.M.2
Dunaway, T.3
Rojavin, M.A.4
Stein, M.R.5
-
73
-
-
84920277941
-
-
ALPI-studien Att Leva med Primär Immunbrist Vuxenrapport. Rapport 1 [The SwePID study; to live with a primary immunodeficiency. Report regarding adults. Report 1/2007]. Stockholm: Karolinska Institutet
-
Gardulf A, Hansen S, Elnersson K etal. ALPI-studien Att Leva med Primär Immunbrist Vuxenrapport. Rapport 1 [The SwePID study; to live with a primary immunodeficiency. Report regarding adults. Report 1/2007]. Stockholm: Karolinska Institutet, 2007.
-
(2007)
-
-
Gardulf, A.1
Hansen, S.2
Elnersson, K.3
-
74
-
-
84920287577
-
-
Talecris Biotherapeutics, Inc., Research Triangle Park, NC: Grifols, USA.
-
Talecris Biotherapeutics, Inc., Research Triangle Park, NC: Grifols, USA.
-
-
-
-
75
-
-
84920262905
-
-
Baxter Healthcare Corporation, Westlake Village, CA, USA.
-
Baxter Healthcare Corporation, Westlake Village, CA, USA.
-
-
-
-
76
-
-
80052697929
-
Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases
-
Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med 2011; 123:186-193.
-
(2011)
Postgrad Med
, vol.123
, pp. 186-193
-
-
Stein, M.R.1
Koterba, A.2
Rodden, L.3
Berger, M.4
-
77
-
-
84880004959
-
Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push
-
Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol 2013; 173:365-371.
-
(2013)
Clin Exp Immunol
, vol.173
, pp. 365-371
-
-
Shapiro, R.1
-
78
-
-
0027438975
-
Rapid subcutaneous immunoglobulin infusions in children
-
Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet 1993; 342:1432-1433.
-
(1993)
Lancet
, vol.342
, pp. 1432-1433
-
-
Thomas, M.J.1
Brennan, V.M.2
Chapel, H.H.3
-
79
-
-
68949119374
-
Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency
-
Church JA, Borte M, Taki H etal. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency. Pediatr Asthma Allergy Immunol 2009; 22:53-62.
-
(2009)
Pediatr Asthma Allergy Immunol
, vol.22
, pp. 53-62
-
-
Church, J.A.1
Borte, M.2
Taki, H.3
-
80
-
-
0029681943
-
Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93
-
Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child 1996; 74:527-530.
-
(1996)
Arch Dis Child
, vol.74
, pp. 527-530
-
-
Skull, S.1
Kemp, A.2
-
81
-
-
84920263148
-
-
ALPI-studien Att Leva med Primär Immunbrist Föräldrarapport. Rapport 2 [The SwePID study; to live with a primary immunodeficiency. Report regarding parents]. Stockholm: Karolinska Institutet
-
Gardulf A, Hansen S, Elnersson K etal. ALPI-studien Att Leva med Primär Immunbrist Föräldrarapport. Rapport 2 [The SwePID study; to live with a primary immunodeficiency. Report regarding parents]. Stockholm: Karolinska Institutet, 2007.
-
(2007)
-
-
Gardulf, A.1
Hansen, S.2
Elnersson, K.3
-
82
-
-
84920272311
-
-
Use of subcutaneous IgG in patients on concomitant anticoagulant and antiplatelet therapy. Immunoglobulin Nursing Society National Conference, 3-5 August, 2012, Orlando, FL, USA. Conference Proceedings.
-
Stein MR, Farnan K, Eufrasio D etal. Use of subcutaneous IgG in patients on concomitant anticoagulant and antiplatelet therapy. Immunoglobulin Nursing Society National Conference, 3-5 August, 2012, Orlando, FL, USA. Conference Proceedings.
-
-
-
Stein, M.R.1
Farnan, K.2
Eufrasio, D.3
-
83
-
-
0035049375
-
Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women
-
Gardulf A, Andersson E, Lindqvist M, Hansen S, Gustafson R. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol 2001; 21:150-154.
-
(2001)
J Clin Immunol
, vol.21
, pp. 150-154
-
-
Gardulf, A.1
Andersson, E.2
Lindqvist, M.3
Hansen, S.4
Gustafson, R.5
-
84
-
-
84920268682
-
-
UK Department of Health. Clinical guidelines for immunoglobulin use: update to second edition. London, UK
-
UK Department of Health. Clinical guidelines for immunoglobulin use: update to second edition. London, UK, 2011.
-
(2011)
-
-
-
85
-
-
84872651749
-
Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics
-
Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013; 24:49-53.
-
(2013)
Pediatr Allergy Immunol
, vol.24
, pp. 49-53
-
-
Shapiro, R.S.1
-
86
-
-
84892752342
-
Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site
-
Duff C, Ochoa D, Riley P, Murphy E, Zampelli A. Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site. J Infus Nurs 2013; 36:384-390.
-
(2013)
J Infus Nurs
, vol.36
, pp. 384-390
-
-
Duff, C.1
Ochoa, D.2
Riley, P.3
Murphy, E.4
Zampelli, A.5
-
87
-
-
84920261645
-
-
American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. Milwaukee, WI
-
American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. Milwaukee, WI, 2011.
-
(2011)
-
-
-
88
-
-
0023735488
-
Immunoglobulin replacement therapy by self-infusion at home
-
Chapel H, Brennan V, Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 1988; 73:160-162.
-
(1988)
Clin Exp Immunol
, vol.73
, pp. 160-162
-
-
Chapel, H.1
Brennan, V.2
Delson, E.3
-
89
-
-
0029303667
-
Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy
-
Gardulf A, Bjorvell H, Andersen V etal. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21:917-927.
-
(1995)
J Adv Nurs
, vol.21
, pp. 917-927
-
-
Gardulf, A.1
Bjorvell, H.2
Andersen, V.3
-
90
-
-
34547893864
-
Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration
-
Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4:427-440.
-
(2007)
Expert Opin Drug Deliv
, vol.4
, pp. 427-440
-
-
Frost, G.I.1
-
91
-
-
84869122138
-
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
-
Wasserman RL, Melamed I, Stein MR etal. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130:951-957.
-
(2012)
J Allergy Clin Immunol
, vol.130
, pp. 951-957
-
-
Wasserman, R.L.1
Melamed, I.2
Stein, M.R.3
-
92
-
-
84920278154
-
-
European Medicines Agency (EMA). HyQvia. Summary of product characteristics
-
European Medicines Agency (EMA). HyQvia. Summary of product characteristics, 2014.
-
(2014)
-
-
-
93
-
-
84920285871
-
-
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] [package insert]. US License no. 140. Westlake Village, CA, USA: Baxter Healthcare Corporation
-
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] [package insert]. US License no. 140. Westlake Village, CA, USA: Baxter Healthcare Corporation, 2014.
-
(2014)
-
-
-
94
-
-
34247279262
-
Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route
-
Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21:105-116.
-
(2007)
BioDrugs
, vol.21
, pp. 105-116
-
-
Gardulf, A.1
-
95
-
-
0141574289
-
Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy
-
Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003; 61:213-217.
-
(2003)
Neth J Med
, vol.61
, pp. 213-217
-
-
Eijkhout, H.W.1
van den Broek, P.J.2
van der Meer, J.W.3
-
96
-
-
0342506487
-
Prophylactic therapy for selective IgA deficiency
-
Gustafson R, Gardulf A, Granert C, Hansen S, Hammarstrom L. Prophylactic therapy for selective IgA deficiency. Lancet 1997; 350:865.
-
(1997)
Lancet
, vol.350
, pp. 865
-
-
Gustafson, R.1
Gardulf, A.2
Granert, C.3
Hansen, S.4
Hammarstrom, L.5
-
97
-
-
0031802363
-
Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy
-
Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112:341-346.
-
(1998)
Clin Exp Immunol
, vol.112
, pp. 341-346
-
-
Sundin, U.1
Nava, S.2
Hammarstrom, L.3
-
98
-
-
84897027403
-
A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG
-
Lozano-Blasco J, Martin-Mateos MA, Alsina L etal. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG. Allergol Immunopathol (Madr) 2012; 42:136-141.
-
(2012)
Allergol Immunopathol (Madr)
, vol.42
, pp. 136-141
-
-
Lozano-Blasco, J.1
Martin-Mateos, M.A.2
Alsina, L.3
-
99
-
-
67349234104
-
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency
-
Wasserman RL, Church JA, Peter HH etal. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009; 37:272-278.
-
(2009)
Eur J Pharm Sci
, vol.37
, pp. 272-278
-
-
Wasserman, R.L.1
Church, J.A.2
Peter, H.H.3
-
100
-
-
79955837379
-
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency
-
Wasserman RL, Melamed I, Nelson RP etal. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011; 50:405-414.
-
(2011)
Clin Pharmacokinet
, vol.50
, pp. 405-414
-
-
Wasserman, R.L.1
Melamed, I.2
Nelson, R.P.3
-
101
-
-
84920278026
-
-
Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, November 8-13, Anaheim, CA, USA. Conference Proceedings: P221.
-
Koterba A, Farnan K, Sierra C, Eufrasio D, Stein MR. Experience with subcutaneous loading of Vivaglobin® or Hizentra® in primary immunodeficiency patients naive to immunoglobulin replacement therapy. Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, November 8-13 2012, Anaheim, CA, USA. Conference Proceedings: P221.
-
(2012)
Experience with subcutaneous loading of Vivaglobin® or Hizentra® in primary immunodeficiency patients naive to immunoglobulin replacement therapy
-
-
Koterba, A.1
Farnan, K.2
Sierra, C.3
Eufrasio, D.4
Stein, M.R.5
|